The domestic nine-valent HPV vaccine is expected to be launched in 2025, which will ease the demand

  Yangcheng Evening News reporter Chen Liang and Zhang Hua

  Intern Hong Jiaxun

  Recently, Jiangsu colleges and universities introduced the nine-valent HPV (human papillomavirus) vaccine, which is scarce on the market, as a "gift" on Women's Day and rushed to the hot search.

On March 8, Nanjing University of Science and Technology introduced 3,000 copies of MSD's nine-valent HPV vaccine, and Nanjing University of Posts and Telecommunications introduced 2,000 copies of nine-valent HPV vaccine. All female teachers and students in the school are open to appointment channels and vaccinated at their own expense.

  The HPV nine-valent vaccine is "hard to get a shot", and the problem of out-of-stock has always plagued the majority of women.

This time, two domestic colleges and universities can provide such a large-scale reservation volume at one time. Can female teachers and students in Guangdong colleges and universities also have such "benefits"?

When will the shortage of vaccines be resolved?

All media reporters from the Yangcheng Evening News conducted an investigation and interview for this.

  Some Guangdong universities have opened a small number of vaccination places

  What the neighbors are most concerned about is whether teachers and students in Guangdong colleges and universities can also enjoy such "welfare"?

The reporter learned that some universities in Guangdong have also provided vaccination places.

Since last year, the campus hospitals of South China Normal University and South China Agricultural University have successively introduced quadrivalent and nine-valent HPV vaccines, which are limited to female students, female employees and female residents within their jurisdiction.

  On Women's Day, Huanong provided 15 copies of the quadrivalent HPV vaccine and 10 copies of the nine-valent HPV vaccine. The vaccination work was carried out by the vaccination clinic of Huanong Hospital (Huanong Community Health Service Center).

  According to reports, since September 2021, the center has been conducting trial appointments for vaccinations based on the supply of vaccines, publicizing it through the official account of the school hospital, through trains in the Internet Office lobby, and pushing on the homepage of the campus website, and online appointments to grab numbers. , to carry out vaccination work.

At present, the self-paid prices are 831 yuan/injection (four prices) and 1331 yuan/injection (nine prices), respectively. The Tianhe District Center for Disease Control and Prevention formulates the supply plan, quota and unified distribution.

  China Normal University has launched the HPV vaccine appointment notice on the public account of "South China Normal University Hospital" four times, allowing female residents of China Normal University and female teachers and students to register through the WeChat applet.

The price of the vaccine is the same as that of Huanong, but each appointment is a complete course of treatment, including three vaccine injections.

At present, the HPV vaccine is only available at the Shipai campus. Teachers, students and residents of other campuses who have successfully made an appointment need to go to the Shipai campus to be vaccinated.

  It is reported that Huagong began to provide HPV vaccine as early as the end of 2017, which was provided by the Tianhe District Center for Disease Control and Prevention.

Since October 2021, vaccination services have been provided every Tuesday and Thursday, with 17 doses per day. In the future, we will strive for more and more stable vaccine supply.

In order to effectively serve the people in this community, at present, the vaccine can only be reserved through the campus intranet, and the number will be assigned by the computer.

  Due to the large number of women of the right age, the limited supply of vaccines can be considered "a drop in the bucket" for the majority of college teachers and students.

  Vaccine supply companies are increasing production capacity to supply China

  For a long time, the nine-valent HPV vaccine has been "hard to find" in the market.

Why is there such a shortage?

  It is understood that there are currently bivalent, quadrivalent and nine-valent HPV vaccines on the market. Bivalent and quadrivalent HPV vaccines can prevent about 80% of cervical cancers, and nine-valent vaccines can prevent more than 90% of cervical cancers. Currently, they are the only vaccines that can prevent HPV52 , Type 58 vaccine.

  Qiao Youlin, a professor at the School of Group Medicine and Public Health of Peking Union Medical College, said that the imported bivalent and quadrivalent HPV vaccines had undergone 8 years of clinical trials, but when the nine-valent HPV vaccine was introduced, the State Food and Drug Administration would issue a notification within 9 days. Conditionally approved.

The vaccine is for women between the ages of 16 and 26 to prevent cervical cancer caused by HPV.

Merck, the vaccine supplier, did not expect to be listed in China within 9 days, so the production plan has not been able to keep up.

  How to solve the "out of stock" problem?

Li Xiaomao, a professor of gynecology at the First Affiliated Hospital of Sun Yat-sen University, introduced to reporters that the currently imported nine-valent HPV vaccine has been applied for the indications of 9-15-year-old mainland women, that is, the applicable population has expanded from the original 16-26 years old. The indication application is expected to be approved within this year.


Merck is increasing its production capacity and expects to double the supply of the nine-valent HPV vaccine in China in 2022.

  It is understood that the domestic nine-valent HPV vaccine is undergoing Phase III clinical trials and is expected to be officially launched in 2025.

By then, the domestic supply of HPV vaccine will be greatly eased.

  Knowledge D

  HPV vaccine pushes the world

  Achieving the goal of eliminating cervical cancer

  Cervical cancer is the most common gynecological malignancy.

The high incidence of carcinoma in situ is 30 to 35 years old, and the age of invasive carcinoma is 45 to 55 years old. In recent years, the incidence has been younger.

According to statistics, more than 80% of women have at least one HPV infection in their lifetime, and it is now clear that more than 99% of cervical cancers are related to persistent HPV infection.

  The birth of HPV vaccine makes cervical cancer expected to become the first malignant tumor that can be completely eliminated.

At present, the HPV vaccines approved for marketing in my country include two bivalent vaccines, one quadrivalent vaccine and one ninevalent vaccine.

The National Health and Medical Commission stated that my country will fully support the "Global Strategy to Accelerate the Elimination of Cervical Cancer" proposed by the World Health Organization.

  There are fourteen types of high-risk human papillomaviruses for cervical cancer, of which 16 and 18 are the most common types, which can cause about 80% of cervical cancers.

The bivalent vaccine protects against HPV16 and 18 viruses; the quadrivalent vaccine increases the prevention of HPV6 and 11 viruses on the basis of bivalent; Type 52, type 58 virus.